Drooling Reduction Intervention randomised trial (DRI): comparing the efficacy and acceptability of hyoscine patches and glycopyrronium liquid on drooling in children with neurodisability.

<bold>Objective: </bold>Investigate whether hyoscine patch or glycopyrronium liquid is more effective and acceptable to treat drooling in children with neurodisability.<bold>Design: </bold>Multicentre, single-blind, randomised controlled trial.<bold>Setting: </bold>Recruitment through neurodisability teams; treatment by parents.<bold>Participants: </bold>Ninety children with neurodisability who had never received medication for drooling (55 boys, 35 girls; median age 4 years).<bold>Exclusion Criteria: </bold>medication contraindicated; in a trial that could affect drooling or management.<bold>Intervention: </bold>Children were randomised to receive a hyoscine skin patch or glycopyrronium liquid. Dose was increased over 4 weeks to achieve optimum symptom control with minimal side-effects; steady dose then continued to 12 weeks.<bold>Primary and Secondary Outcomes: </bold>Primary outcome: Drooling Impact Scale (DIS) score at week-4.<bold>Secondary Outcomes: </bold>change in DIS scores over 12 weeks, Drooling Severity and Frequency Scale and Treatment Satisfaction Questionnaire for Medication; adverse events; children's perception about treatment.<bold>Results: </bold>Both medications yielded clinically and statistically significant reductions in mean DIS at week-4 (25.0 (SD 22.2) for hyoscine and 26.6 (SD 16) for glycopyrronium). There was no significant difference in change in DIS scores between treatment groups. By week-12, 26/47 (55%) children starting treatment were receiving hyoscine compared with 31/38 (82%) on glycopyrronium. There was a 42% increased chance of being on treatment at week-12 for children randomised to glycopyrronium relative to hyoscine (1.42, 95% CI 1.04 to 1.95).<bold>Conclusions: </bold>Hyoscine and glycopyrronium are clinically effective in treating drooling in children with neurodisability. Hyoscine produced more problematic side effects leading to a greater chance of treatment cessation.<bold>Trial Registration Numbers: </bold>ISRCTN 75287237; EUDRACT: 2013-000863-94; Medicines and Healthcare Products Regulatory Agency: 17136/0264/001-0003. [ABSTRACT FROM AUTHOR]